CRISPR that switches a backup gene back on: what the sickle cell editing trial showed
Editing one genetic 'switch' to reawaken a silenced backup gene turned CRISPR from a lab tool into a working therapy for inherited blood disease.
What the study found
In a 2021 New England Journal of Medicine report, researchers treated a patient with sickle cell disease and a patient with transfusion-dependent beta-thalassemia using exagamglogene autotemcel (exa-cel). They removed each patient's own blood-forming (CD34+) stem cells, used CRISPR-Cas9 to disable a regulatory region (the erythroid enhancer of BCL11A), and returned the edited cells. Disabling that switch reawakens fetal hemoglobin — a form the body normally silences after birth. Both patients produced high levels of fetal hemoglobin; the sickle cell patient had no vaso-occlusive crises and the thalassemia patient became transfusion-independent over the follow-up reported.
Why the target matters
Sickle cell disease and beta-thalassemia are both caused by problems with adult hemoglobin. Rather than repair the broken gene directly, this approach turns a healthy backup — fetal hemoglobin — back on. That is why a single edit can help two different diseases that share the same downstream molecule.
Analysis — the pattern we're watching
Read alongside the wider field, a pattern stands out (this is analysis, not a settled claim): "reactivate a developmentally silenced backup gene" is emerging as a reusable strategy across the hemoglobin disorders, and BCL11A keeps recurring as the switch that multiple independent programs aim at. The FDA's later approval of an exa-cel-based therapy in 2023 is consistent with the durability suggested early on. A separate, still-unproven direction is performing the edit inside the body (in vivo) to avoid the harsh chemotherapy conditioning that today's ex vivo editing requires — promising on paper, not yet demonstrated at scale.
What's still uncertain
This was a small, early report. The editing is done outside the body and still requires myeloablative conditioning, which carries real risks. Long-term durability, safety across many patients, and access and cost all remain open questions.